Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Notes Payables (2018)

Organogenesis Holdings has reported Notes Payables over the past 1 years, most recently at $15.9 million for Q4 2018.

  • Quarterly results put Notes Payables at $15.9 million for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $15.9 million (changed N/A YoY), and the annual figure for FY2018 was $15.9 million, changed.
  • Notes Payables for Q4 2018 was $15.9 million at Organogenesis Holdings.
  • Over the last five years, Notes Payables for ORGO hit a ceiling of $15.9 million in Q4 2018 and a floor of $15.9 million in Q4 2018.